Current knowledge on the mechanisms of action of viruses in the development of airway inflammation and the involvement of the innate immune response, especially in the activation of ILC2s and epithelial cell-derived cytokines called alarmins, including IL-25, IL-33, and TSLP;, and the timely inhibition of the epithelial RIG-1 inflammasome, open a window of opportunity for the use of new drugs, mainly biologics, in the prevention and treatment of asthma exacerbations due to viral infections. This evidence concerns the gene IL33 and asthma.